肝动脉置管持续灌注化疗和栓塞联合全身静脉化疗治疗结直肠癌肝转移的疗效观察  

Observation of therapeutic effect of transcatheter hepatic arterial chemoembolization combined with continuous hepatic artery infusion and intravenous chemotherapy for patients with unresectable liver metastasis from colorectal cancer

作　　者：李毅[1] 卿毅[1] 廖正银[2] 顾咸庆[1] 谢家印[1] 梁伟[1] 彭娜[1] 王东[1] 

机构地区：[1]第三军医大学大坪医院野战外科研究所肿瘤中心,重庆400042 [2]四川大学华西医院肿瘤二科,成都610041

出　　处：《重庆医学》2012年第29期3046-3048,共3页Chongqing medicine

摘　　要：目的研究FOLFOX4方案的肝动脉化疗栓塞联合肝动脉置管持续灌注化疗及静脉化疗对治疗结直肠癌肝转移的有效性及安全性。方法对50例诊断结直肠癌肝转移行FOLFOX4方案的肝动脉化疗栓塞联合肝动脉置管持续灌注及全身静脉化疗患者评价近期疗效并随访其生存状况。结果 50例患者中有46例可评价近期疗效,无CR病例,PR 20例,SD 15例,PD11例;所有患者无Ⅲ级以上不良反应发生;1、2、3年生存率分别为71.4%、36.7%、10.4%,中位生存期19.7个月。结论基于FOLFOX4方案肝动脉化疗栓塞联合肝动脉置管持续灌注及全身静脉化疗治疗结直肠癌肝转移具有良好的近期疗效和总生存期,患者耐受力良好,联合治疗具备良好的治疗前景。Objective To study the therapeutic safety and efficacy of FOLFOX4-based TACE combined with continuous hepatic artery infusion and intravenous chemotherapy for patients with unresectable liver metastasis from colorectal cancer. Methods A total of 50 patients with unresectable liver metastasis from colorectal cancer were treated with continuous hepatic artery infusion and intravenous chemotherapy combined with TACE. Short- and long-term effects including initial treatment response, survival and treatment-related complications were assessed. Results The therapeutic effects of 46 patients could be assessed,no CR patient,20 cases of PR,15 cases of SD,11 cases of PD. There were no exceeded III grade side effects or treatment-related complications. The 1-,3- and 5-year survival rates were 71.4% ,36.7% and 10.4% ,respectively. Median survival time was 19.7 months. Conclusion Continuous hepatic artery infusion and intravenous chemotherapy combined with TACE may be useful for patients with unresectable liver metastasis from colorectal cancer and side effects could be tolerant. Combined treatment may have a good prospect, but further prospective randomized control studies are needed to confirm this treatment modality.

关 键 词：结直肠肿瘤 肿瘤转移 肝动脉栓塞化疗 动脉持续灌注化疗 FOLFOX4 

分 类 号：R735.3[医药卫生—肿瘤]